You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Trilaciclib; HR-Negative Breast Cancer; Adjuvant Therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

Breast Tumor Trial (Trilaciclib plus chemo, Chemotherapy)

Not yet recruiting
  • Breast Neoplasm
  • (no location specified)
May 8, 2023

Metastatic Triple-Negative Breast Cancer Trial in Charlotte (Trilaciclib, Pembrolizumab, Gemcitabine)

Not yet recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Charlotte, North Carolina
    Levine Cancer Institute
Aug 31, 2023

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)

Recruiting
  • Breast Cancer
  • Capecitabine+endocrine therapy
  • Placebo+endocrine therapy
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jun 5, 2023

Breast Cancer Trial in Tianjin (Dalcelli?Exemestane?Gosserine, Docetaxel for injection?Epirubicin HCl for

Recruiting
  • Breast Cancer
  • Tianjin, Tianjin, China
    Jie Ge
Aug 20, 2023

Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer

Active, not recruiting
  • Hormone-receptor-positive Breast Cancer
  • +2 more
  • No drug
  • Cambridge, Massachusetts
    ConcertAI database
Sep 8, 2023

Triple Negative Breast Cancer, Breast Cancer Trial in United States (Trilaciclib, Cylophosphamide, Doxorubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Breast Cancer
  • Los Alamitos, California
  • +6 more
Jan 25, 2023

Breast Cancer Trial in Beijing, Guangzhou (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole,

Not yet recruiting
  • Breast Cancer
  • TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
  • Placebo capsules, Letrozole, Anastrozole, Tamoxifen
  • Beijing, Beijing, China
  • +1 more
Mar 10, 2023

Hormone Receptor-positive Advanced Breast Cancer Trial (chidamide combined with fulvestrant)

Not yet recruiting
  • Hormone Receptor-positive Advanced Breast Cancer
  • chidamide combined with fulvestrant
  • (no location specified)
Mar 28, 2023

Breast Cancer, Triple Negative Breast Cancer Trial (Antivascular therapy, Chemotherapy)

Not yet recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • (no location specified)
Jun 11, 2023

HR+/HER2- Advanced Breast Cancer, Targeted Therapy Trial in Beijing (Everolimus, Chidamide, Endocrine therapy)

Recruiting
  • HR+/HER2- Advanced Breast Cancer
  • Targeted Therapy
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Aug 1, 2023

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    HR Positive HER2 Negative Advanced Breast Cancer Trial in Tianjin (Chidamide)

    Recruiting
    • HR Positive HER2 Negative Advanced Breast Cancer
    • Tianjin, China
      天津市肿瘤医院
    May 26, 2023

    Early Breast Cancer Trial (Ribociclib, Letrozole, Ansastrozole)

    Not yet recruiting
    • Early Breast Cancer
    • (no location specified)
    Apr 12, 2023

    Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;

    Recruiting
    • Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
    • dalpiciclib; fluvestrant; compound gossypol acetate tablets
    • Hangzhou, Zhejiang, China
      zhejiangCH
    Nov 9, 2023

    Breast Cancer Trial in Guangzhou (Chidamide Plus Toripalimab Plus Paclitaxel)

    Recruiting
    • Breast Cancer
    • Chidamide Plus Toripalimab Plus Paclitaxel
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Feb 19, 2023

    Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

    Not yet recruiting
    • Breast Cancer
    • Ovarian Function Suppression + Aromatase Inhibitor
    • Adjuvant Chemotherapy + Ovarian Function Suppression
    • (no location specified)
    May 19, 2023

    Breast Cancer Female, Triple Negative Breast Cancer Trial (quercetin, EGCG, metformin , zinc)

    Not yet recruiting
    • Breast Cancer Female
    • Triple Negative Breast Cancer
    • quercetin, EGCG, metformin , zinc
    • (no location specified)
    Dec 23, 2022

    Breast Cancer Trial in Chengdu (Dalpiciclib combined with Letrozole)

    Not yet recruiting
    • Breast Cancer
    • Dalpiciclib combined with Letrozole
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Aug 3, 2023

    Breast Cancer Trial (Disitamab Vedotin+Anlotinib)

    Not yet recruiting
    • Breast Cancer
    • Disitamab Vedotin+Anlotinib
    • (no location specified)
    Aug 14, 2023

    Breast Cancer, Chemo Effect Trial (Capecitabine)

    Not yet recruiting
    • Breast Cancer
    • Chemotherapy Effect
    • (no location specified)
    Mar 9, 2022

    TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • (no location specified)
    May 8, 2023

    Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

    Not yet recruiting
    • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
    • (no location specified)
    Sep 26, 2023